Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10281228 | 0.90 | PTGS2 (0.75) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL5071839 | 0.89 | PTGS2 (0.73) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL29593653 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL24645 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL28723602 | 0.87 | PTGS2 (0.98) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL6601340 | 0.87 | PTGS2 (0.98) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL5074502 | 0.86 | PTGS2 (0.69) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL5070971 | 0.85 | PTGS2 (0.67) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL6599167 | 0.83 | PTGS2 (0.91) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL7876584 | 0.82 | PTGS2 (0.73) | PTGS2PTGS1ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | PTGS2 2601/4885PTGS1 2676/4885ABCB11 34/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | PTGS2 2601/4885PTGS1 2676/4885ABCB11 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.